Alan Sharpe
AstraZeneca (Australia)(AU)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Gene expression and cancer classification, Molecular Biology Techniques and Applications, Cancer Genomics and Diagnostics, Computational Drug Discovery Methods
Most-Cited Works
- → PD-1 and its ligands in T-cell immunity(2007)419 cited
- → Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples(2015)325 cited
- → Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer(2017)303 cited
- → Comparisons between FLUENT and ADMS for atmospheric dispersion modelling(2003)248 cited
- → Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)(2016)145 cited
- → PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer(2018)62 cited
- → Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study(2019)56 cited
- → Photo-induced environmental depletion processes of β-blockers in river waters(2009)49 cited
- Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.(1998)
- → Are Toxicological Responses in Laboratory (Inbred) Zebrafish Representative of Those in Outbred (Wild) Populations? − A Case Study with an Endocrine Disrupting Chemical(2011)49 cited